Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Pfizer’s Celebrex found to be no riskier for hearts than other rival pain drugs A new study has found that Pfizer’s arthritis drug Celebrex (celecoxib) posed no higher risk to a patient’s heart when compared to its rivals, Ibuprofen and Naproxen. Drug Research > Drug Delivery > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

GlobalData says NSCLC market will increase to $26.71bn by 2025
Research and consulting firm GlobalData said the non-small cell lung cancer (NSCLC) market across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to increase to $26.71bn by 2025 from $6.21bn in 2015, representing a very strong compound annual growth rate of 15.7%.
Drug Research > Drug Delivery > News
FDA approves DARZALEX for relapsed multiple myeloma
Genmab has secured approval from the US Food and Drug Administration (FDA) to use DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Bicycle, AstraZeneca enter into potential $1bn multitarget collaboration
By PBR Staff Writer
Bicycle Therapeutics and AstraZeneca have agreed a $1bn multi-target collaboration across respiratory, cardiovascular and metabolic diseases.
Drug Research > Drug Discovery & Development > News
Evotec, Merck sign deals to partner on target discovery technologies
Evotec and Merck have signed agreements to collaborate on target discovery technologies.
Drug Research > Drug Discovery & Development > News